Article
Oncology
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Helene Labussiere-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jurgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of CBT and single-allele-mismatched MMUD allo-HCT with PTCy in acute myeloid leukemia. The results showed that CBT was associated with higher incidence of graft failure and non-relapse mortality compared to MMUD, leading to lower leukemia-free survival, overall survival, and GVHD-free, relapse-free survival. In conclusion, MMUD allo-HCT with PTCy may be a preferred choice over CBT for patients without a fully matched donor.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jaroslaw Dybko, Malgorzata Sobczyk-Kruszelnicka, Sebastian Makuch, Siddarth Agrawal, Krzysztof Dudek, Sebatian Giebel, Lidia Gil
Summary: This study compared the outcomes of patients who received post-transplant cyclophosphamide (PTCy) or conventional immunosuppressants after allogeneic hematopoietic cell transplantation. The study found that patients receiving PTCy had lower rates of acute graft-versus-host disease and cytomegalovirus reactivation, and higher survival rates. Further research with a larger sample size is needed to confirm these results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
Juan Montoro, Elisa Roldan, Jose Luis Pinana, Pere Barba, Pedro Chorao, Abdiel Quintero, Rafael Hernani, Guillermo Orti, Jose Ignacio Lorenzo, Aitana Balaguer-Rosello, Olga Salamero, Laura Fox, Pilar Solves, Ines Gomez, Manuel Guerreiro, Juan Carlos Hernandez Boluda, Guillermo Sanz, Carlos Solano, Miguel Angel Sanz, David Valcarcel, Jaime Sanz
Summary: PTCy-Sir-MMF provides better survival outcomes but is associated with higher risk of cGVHD compared to TCD.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Justin Loke, Hrushikesh Vyas, Charles Craddock
Summary: AML is the most common indication for allo-SCT worldwide, with advancements in risk stratification, donor availability, and conditioning regimens expanding transplant access for high risk patients. Disease relapse remains the top cause of transplant failure, highlighting the need for novel strategies to reduce recurrence risk.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Giorgia Battipaglia, Myriam Labopin, Rose-Marie Hamladji, Didier Blaise, Patrice Chevallier, Eolia Brissot, Armin Gerbitz, Gerard Socie, Boris Afanasyev, Fabio Ciceri, Ellen Meijer, Yener Koc, Jan J. Cornelissen, Anne Huynh, Hakan Ozdogu, Johan Maertens, Franciane Paul, Helene Labussiere-Wallet, Annalisa Ruggeri, Mahmoud Aljurf, Ali Bazarbachi, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: GVHD is a major complication after allo-HSCT. Adding ATG or PTCY to standard immunosuppressive agents can reduce GVHD in different donor settings. Comparing outcomes of AML patients undergoing allo-HSCT from HLA-identical sibling donors with PTCY or ATG, it was found that while the overall outcomes were similar, ATG may be associated with lower incidence of chronic GVHD.
Article
Cell & Tissue Engineering
Robert Puckrin, Alex Chi Fung Kwan, Nikki Blosser, Catherine Leyshon, Peter Duggan, Andrew Daly, Victor Zepeda, Douglas Stewart, Ahsan Chaudhry, Jan Storek, Kareem Jamani
Summary: Corticosteroids are not effective as GVHD prophylaxis for patients with CNI intolerance, as they may increase the risks of acute GVHD and poor outcomes.
Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mark-Alexander Schwarzbich, Hao Dai, Lambros Kordelas, Dietrich W. Beelen, Aleksandar Radujkovic, Carsten Mueller-Tidow, Peter Dreger, Thomas Luft
Summary: The study demonstrates that pre-conditioning serum Leptin levels can serve as an independent prognostic marker for relapse following alloSCT in high-risk acute leukemia patients, particularly those in the intermediate to advanced stages. This effect was validated in an independent cohort, suggesting the potential utility of serum Leptin for predicting post-transplant outcomes in certain patient populations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Raffaella Greco, Francesca Lorentino, Serena Albanese, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Clerici, Lorenzo Lazzari, Magda Marcatti, Sara Mastaglio, Elisabetta Xue, Francesca Farina, Francesca Pavesi, Andrea Assanelli, Matteo G. Carrabba, Sarah Marktel, Luca Vago, Chiara Bonini, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Jacopo Peccatori
Summary: The study examined 249 adult patients undergoing HSCT from haploidentical, HLA-matched related, HLA-matched unrelated, or mismatched related donors. The results showed promising outcomes in terms of GVHD prophylaxis and treatment using PTCy and sirolimus across different donor sources.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Hematology
Rebeca Bailen, Maria Jesus Pascual-Cascon, Manuel Guerreiro, Lucia Lopez-Corral, Anabelle Chinea, Arancha Bermudez, Antonia Sampol, Inmaculada Heras, Estefania Garcia-Torres, Melissa Torres, Jose Rifon Roca, Beatriz Herruzo, Jaime Sanz, Marta Fonseca, Pilar Herrera, Mercedes Colorado, Leyre Bento, Oriana Lopez-Godino, Carmen Martin-Calvo, Paula Fernandez-Caldas, Maria Marcos-Jubilar, Isabel Sanchez-Ortega, Carlos Solano, Victor Noriega, Karem Humala, Gillen Oarbeascoa, Jose Luis Diez-Martin, Mi Kwon
Summary: This retrospective study compared the outcomes of haploidentical and HLA identical HSCT in AML patients using PTCY. The results showed no significant differences in survival outcomes and GVHD between the two groups. However, the incidence of acute GVHD was lower in the HLA identical group.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Dennis L. Cooper, Jacqueline Manago, Vimal Patel, Dale Schaar, Anne Tyno, Yong Lin, Roger Strair
Summary: Posttransplant cyclophosphamide can decrease graft-versus-host disease, supporting current donor selection algorithms. However, the findings of decreased survival and increased NRM in Black patients requires further investigation.
Article
Biophysics
Giorgia Battipaglia, Jacques-Emmanuel Galimard, Myriam Labopin, Anna Maria Raiola, Didier Blaise, Annalisa Ruggeri, Yener Koc, Zafer Guelbas, Antonin Vitek, Simona Sica, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Montserrat Rovira, Ivan Moiseev, Massimo Martino, Giovanni Grillo, Mercedes Colorado Araujo, Claude Eric Bulabois, Stephanie Nguyen, Gerard Socie, Mutlu Arat, Jiri Pavlu, Johanna Tischer, Hans Martin, Lucia Lopez Corral, Goda Choi, Edouard Forcade, Andrew McDonald, Fabrizio Pane, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: The study compared Haploidentical (Haplo) HCT with one-antigen mismatched unrelated donor (1Ag-MMUD) HCT for acute myeloid leukemia (AML) patients in complete remission. It found that Haplo groups had higher non-relapse mortality, lower leukemia-free survival, and overall survival compared to 1Ag-MMUD groups. No significant differences were observed for graft-versus-host/relapse-free survival and relapse incidence.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Abu-Sayeef Mirza, Ankita Tandon, Dakota Jenneman, Shu Cao, Thomas Brimer, Ambuj Kumar, Michelle Kidd, Farhad Khimani, Rawan Faramand, Asmita Mishra, Hien Liu, Taiga Nishihori, Lia Perez, Aleksandr Lazaryan, Nelli Bejanyan, Michael Nieder, Claudio Anasetti, Joseph Pidala, Hany Elmariah
Summary: This study retrospectively analyzed the outcomes and subsequent management of patients with intolerance to the TAC/SIR regimen following allogeneic hematopoietic cell transplantation. The results showed that TAC/SIR intolerance was associated with poorer outcomes, with early intolerance contributing to a higher risk of acute graft-versus-host disease, increased nonrelapse mortality, and inferior survival. Most patients who developed intolerance were switched to alternative two-drug regimens, while those with late intolerance tended to be continued on single-drug therapy.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Kimberley Joanne Hatfield, Oystein Bruserud, Hakon Reikvam
Summary: This study found that the pretransplant lipid profiles can be used for the subclassification of patients and possibly identify those with an increased risk of death due to disease relapse or treatment toxicity. Therapeutic targeting of lipid metabolism should be further explored in these transplant recipients.
Article
Hematology
Feiqiong Gao, Jiawei Zhang, Jianlai Hu, Liming Lin, Yang Xu
Summary: This meta-analysis compared the use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in allogeneic hematopoietic stem cell transplantation (allo-HCT). The results showed that PTCy was associated with lower incidence of aGVHD and NRM compared to ATG, along with better overall survival and progression-free survival, without significant differences in relapse rate and cGVHD incidence. More prospective randomized trials are needed to further validate these findings.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucia Lopez Corral, Rafael Hernani Morales, Valentin Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, Maria Luisa Guerra Dominguez, Jose Maria Sanchez Pina, Alberto Mussetti, Juan Manuel Sancho, Mariana Bastos-Oreiro, Eva Catala, Javier Delgado, Hugo Luzardo Henriquez, Jaime Sanz, Maria Calbacho, Rebeca Bailen, Cecilia Carpio, Jose Maria Ribera, Anna Sureda, Javier Briones, Juan Carlos Hernandez-Boluda, Nuria Martinez Cebrian, Jose Luis Diez Martin, Alejandro Martin, Pere Barba
Summary: This retrospective study evaluated the safety and efficacy of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in relapsed/refractory large B-cell lymphoma (LBCL) outside of clinical trials. The results showed that the real-world experience with these CAR-T cell therapies was comparable to the pivotal trial results.
Article
Hematology
Hanadi Rafii, Annalisa Ruggeri, Chantal Kenzey, Jaime Sanz, Regis Peffault De la Tour, Albert Esquirol, Gerard Michel, Patrice Chevallier, Marie-Therese Rubio, Jan J. Cornelissen, Mauricette Michallet, Fernanda Volt, Monica M. Rivera-Franco, Graziana Maria Scigliuolo, Barbara Cappelli, Vanderson Rocha, Eliane Gluckman
Summary: A retrospective analysis of 10,358 recipients of umbilical cord blood transplantation was conducted to examine the occurrence of subsequent neoplasms (SNs). The study found that although SNs after UCBT are rare, they have a negative impact on long-term survival. Early detection and identification of risk factors can help improve overall survival.
Article
Biophysics
Ibrahim Yakoub-Agha, Raffaella Greco, Francesco Onida, Rafael de la Camara, Fabio Ciceri, Selim Corbacioglu, Harry Dolstra, Bertram Glass, Michelle Kenyon, Donal P. McLornan, Benedicte Neven, Regis Peffault de Latour, Zinaida Peric, Annalisa Ruggeri, John A. Snowden, Anna Sureda, Isabel Sanchez-Ortega
Summary: Clinical patient care for hematopoietic cell transplantation and cellular therapy varies between countries and centers. To harmonize clinical practices, European guidelines will be developed by the EBMT PH&G committee through workshops with experts. These guidelines aim to provide clear and practical recommendations in the absence of international consensus.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Raffaella Greco, Jorinde D. Hoogenboom, Edouard F. Bonneville, Achilles Anagnostopoulos, Angela Cuoghi, Jean-Hugues Dalle, Eva M. Weissinger, Peter Lang, Federica Galaverna, Massimo Martino, Alexei Maschan, Christine Mauz-Korholz, Maddalena Noviello, Jakob Passweg, Jacopo Peccatori, Montserrat Rovira, Carlos Solano, Hendrik Veelken, Andrea Velardi, Eva Maria Wagner-Drouet, Xi Zhang, Fabio Ciceri, Chiara Bonini, Luca Vago, Annalisa Ruggeri, Christian Chabannon
BONE MARROW TRANSPLANTATION
(2023)
Editorial Material
Immunology
Pedro Asensi Canto, Empar Mayordomo, Andrea Dorado, Marta Villalba, Rosana Blanco Manez, Eva Gonzalez, Miguel Salavert, Ana Facal, Pedro Chorao, Aitana Balaguer, Rafael Sivera, Juan Montoro, Juan J. Vilchez, Jose Luis Pinana, Miguel Sanz, Jaime Sanz, Nuria Muelas, Manuel Guerreiro
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Immunology
Estela Gimenez, Manuel Guerreiro, Ignacio Torres, Cristobal Aguilar, Eliseo Albert, Juan Carlos Hernandez-Boluda, Rafael Hernani, Ariadna Perez, Paula Amat, Jose Luis Pinana, Juan Montoro, Carlos Solano, David Navarro
Summary: There is limited information on the natural kinetics of CMV DNAemia and CMV-specific T-cell reconstitution in allo-HSCT recipients undergoing LMV prophylaxis. This study found that CMV DNAemia cleared spontaneously in a high proportion of LMV patients, and LMV patients had a lower degree of CMV-specific T-cell reconstitution compared to non-LMV patients.
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Medicine, General & Internal
Pilar Solves, Javier Marco-Ayala, Miguel Angel Sanz, Ines Gomez-Segui, Aitana Balaguer-Rosello, Ana Facal, Marta Villalba, Juan Montoro, Guillermo Sanz, Javier de la Rubia, Jaime Sanz
Summary: This study compares the transfusion requirements of patients undergoing different modalities of hematopoietic stem cell transplantation (HSCT) over a twelve-year period. The results show that transfusion requirements have significantly increased for matched related donor HSCT, while there were no significant changes for matched unrelated donor and haploidentical transplant HSCT.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, David Martinez-Cuadron, Evelyn Acuna-Cruz, Laura Torres-Minana, Rebeca Rodriguez-Veiga, Irene Navarro-Vicente, David Martinez-Campuzano, Raquel Garcia-Ruiz, Pilar Lloret, Pedro Asensi, Ana Osa-Saez, Jaume Aguero, Maria Rodriguez-Serrano, Francisco Buendia-Fuentes, Juan Eduardo Megias-Vericat, Beatriz Martin-Herreros, Eva Barragan, Claudia Sargas, Maribel Salas, Margaret Wooddell, Charles Dharmani, Miguel A. Sanz, Javier De la Rubia, Pau Montesinos
Summary: The incidence and risk factors of cardiac events in acute myeloid leukemia (AML) patients were investigated. A high incidence of cardiac events (58.5%) and significant mortality (3.6%) were observed among treated patients. Relevant cardiac antecedents, age ≥65, and non-intensive chemotherapy were associated with non-fatal cardiac events. Prior heart disease was a significant risk factor for fatal cardiac events. Intensive therapy patients experiencing grade 3-4 cardiac events had decreased overall survival. Identification of prognostic factors can help in monitoring and managing high-risk patients.
Article
Biophysics
Gerard Socie, Pere Barba, Arie Barlev, Jaime Sanz, Irene Garcia-Cadenas, Patrice Chevallier, Franca Fagioli, Norma Guzman-Becerra, Deepali Kumar, Per Ljungman, Arnaud Pigneux, Natalia Sadetsky, Lucrecia Yanez San Segundo, Mazyar Shadman, Jan Storek, Dhanalakshmi Thirumalai, Baodong Xing, Mohamad Mohty
Summary: EBV+ PTLD is a rare and aggressive condition that may occur following HCT. Treatment options are limited and prognosis is poor for patients with R/R EBV+ PTLD.
BONE MARROW TRANSPLANTATION
(2023)
Review
Immunology
Jose L. Pinana, Ariadna Perez, Pedro Chorao, Manuel Guerreiro, Irene Garcia-Cadenas, Carlos Solano, Rodrigo Martino, David Navarro
Summary: Before COVID-19, common community-acquired seasonal respiratory viruses (CARVs) posed a significant threat to allo-HCT recipients. The pandemic has further highlighted the risk for immunosuppressed patients, including allo-HCT recipients, when infected with SARS-CoV-2. As CARVs circulate again, understanding the current state of knowledge and recent advances regarding CARV infection in allo-HCT recipients is crucial for prevention and research.
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Oncology
Elisa Gonzalez-Romero, Cristina Martinez-Valiente, Gema Garcia-Garcia, Antonio Rosal-Vela, Jose Maria Millan, Miguel Angel Sanz, Guillermo Sanz, Alessandro Liquori, Jose Vicente Cervera, Rafael P. Vazquez-Manrique
Summary: We developed a PCR-based alternative strategy for generating CRISPR constructs and successfully edited two genes (IDH2 and MYBL2) in hard-to-transfect leukemic cells. The efficiency of our methodology was similar to that of ribonucleoprotein strategies, without any off-target events. Our strategy provides a valid and intuitive alternative for introducing desired mutations into hard-to-transfect leukemic cells without viral transduction.
Article
Hematology
Pedro Chorao, Juan Montoro, Aitana Balaguer-Rosello, Manuel Guerreiro, Marta Villalba, Ana Facal, Pilar Solves, Ines Gomez-Segui, Marcelo C. Pasquini, Pablo Granados, Ana Bataller, Alberto Louro, Javier de la Rubia, Miguel A. Sanz, Jaime Sanz
Summary: A study comparing bone marrow transplantation and peripheral blood transplantation for severe aplastic anemia found that peripheral blood transplantation led to faster recovery of bone marrow and platelets, as well as a lower incidence of acute GVHD. These findings suggest that peripheral blood could be a safer alternative to bone marrow for transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Meeting Abstract
Oncology
Javier de la Rubia, Juan Montoro, Jaime Sanz, Aitana Balaguer, Manuel Guerreiro, Ana Facal, Marta Villalba, Pedro Chorao, Mario Arnao, Alberto Louro, Miguel Sanz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
